The research, led by Zengchao Shen and colleagues at Lishui Municipal Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, began with a deceptively simple experimental strategy. The team took NCI-N87 gastric cancer cells, which are normally killed by trastuzumab, and exposed them stepwise to increasing concentrations of the drug over an extended period. What emerged were NCI-N87/TR cells, a resistant line that could survive doses of trastuzumab that would annihilate the parental population. These resistant cells became the model for dissecting exactly what had changed at the molecular level to allow survival.

When the researchers compared gene expression between resistant and parental cells, one protein stood out dramatically: NEK2, a serine-threonine kinase best known for its role in centrosome separation during mitosis. NEK2 was markedly upregulated in the trastuzumab-resistant cells, consistent with a growing body of evidence implicating the kinase in cancer progression and therapeutic resistance across multiple tumor types. Previous work has linked NEK2 to proliferation, migration, and drug resistance in gastric cancer through pathways including AKT signaling, ERK/MAPK signaling, and regulation of histone methylation, but its involvement in trastuzumab resistance had never been established.

To test whether NEK2 was merely a bystander or an active participant in resistance, the team used genetic silencing to knock down NEK2 expression in the resistant cells. The results were striking. With NEK2 silenced, cell viability dropped, DNA replication as measured by EdU incorporation declined, and apoptosis increased, indicating that the cells had lost much of their ability to withstand trastuzumab. Conversely, when the researchers forced NEK2 overexpression in parental cells, the cells became more resistant to the drug. The supplementary data confirmed this in a second gastric cancer line, SNU-216, where NEK2 overexpression shifted the dose-response curve and increased survival at trastuzumab concentrations that would normally be lethal.

Having established that NEK2 drives resistance, the team turned to the question of how a mitotic kinase could influence a cell’s response to an antibody that targets a cell-surface receptor. The answer, it turns out, lies in the emerging field of epitranscriptomics, the study of chemical modifications to RNA. The researchers found that NEK2 promotes the expression of fibronectin 1, or FN1, an extracellular matrix protein that has been repeatedly associated with gastric cancer progression and with resistance to various therapies. FN1 activates PI3K/AKT signaling, a pro-survival pathway that helps cells resist apoptosis, and exogenous FN1 partially rescued the resistance lost when NEK2 was knocked down.

But the mechanism went deeper than simple transcriptional regulation. Using RNA immunoprecipitation, MeRIP-qPCR, and dual-luciferase reporter assays, the team discovered that FN1 messenger RNA carries a specific m6A modification at nucleotide 5882, and that this modification is deposited by WTAP, a well-known m6A methyltransferase component. Once the methyl group is in place, the reader protein YTHDF1 recognizes the modified RNA and enhances its stability and translation, boosting FN1 protein production. In other words, NEK2 does not directly increase FN1 transcription; instead, it orchestrates a chain of RNA-level events that keeps FN1 messenger RNA alive longer and translated more efficiently.

The epitranscriptomic circuit proved functionally significant. When the researchers overexpressed either WTAP or YTHDF1 in cells where NEK2 had been silenced, FN1 expression returned, AKT phosphorylation was restored, and trastuzumab resistance came back. This rescue experiment demonstrated that the WTAP/YTHDF1 axis is not merely correlated with resistance but is causally responsible for it, acting downstream of NEK2. The finding places NEK2 at the top of a signaling hierarchy that flows through RNA methylation machinery to control a key extracellular matrix protein and, ultimately, the survival pathway that protects gastric cancer cells from trastuzumab.

The implications for clinical practice are considerable. Trastuzumab resistance in HER2-positive gastric cancer has been attributed to a variety of mechanisms, including HER2 loss, activation of alternative signaling pathways such as Wnt/beta-catenin and STAT3, and changes in the tumor microenvironment. The new study adds a fundamentally different layer to this picture, suggesting that the chemical modification state of messenger RNA can determine whether a tumor responds to targeted therapy. Because m6A modification is reversible and the enzymes involved are drug-targetable, the WTAP/YTHDF1/FN1 axis represents a potential vulnerability that could be exploited pharmacologically.

NEK2 itself has attracted growing interest as a therapeutic target. Recent reviews have catalogued a range of NEK2 inhibitors under development as antitumor agents, and studies in pancreatic cancer, multiple myeloma, and hepatocellular carcinoma have shown that blocking NEK2 can sensitize tumors to other treatments, including immune checkpoint inhibitors and proteasome inhibitors. The current findings suggest that combining NEK2 inhibition with trastuzumab, or targeting the downstream m6A machinery, could be a rational strategy to overcome resistance in gastric cancer patients whose tumors have stopped responding to HER2-directed therapy.

As with any cell-line study, the findings will need validation in patient tumors and animal models before they can inform treatment decisions. The researchers note that their work was conducted in established gastric cancer cell lines, and the datasets used in the study are available from the corresponding author on reasonable request. Nevertheless, the identification of a specific m6A site on FN1 messenger RNA, at a defined nucleotide position, and the demonstration that this single chemical mark can influence a clinically important drug response, represent a compelling example of how RNA modifications are moving from the bench to the forefront of cancer medicine. For patients with HER2-positive gastric cancer facing the prospect of trastuzumab failure, the study offers a molecular explanation for resistance and a set of new targets that may one day restore the effectiveness of one of oncology’s most important targeted therapies.

Subject of Research: Molecular Biology

Article Title: NEK2 promotes trastuzumab resistance in gastric cancer through WTAP/YTHDF1-dependent m6A regulation of FN1

Article References: Shen, Z., Zheng, J., Chen, Y., Liu, J., Li, M., & Shi, H. (2026). NEK2 promotes trastuzumab resistance in gastric cancer through WTAP/YTHDF1-dependent m6A regulation of FN1. Molecular Biology Reports, 53(1), Article 1738. https://doi.org/10.1007/s11033-026-12927-z

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12927-z

Keywords: gastric cancer, trastuzumab resistance, NEK2, m6A modification, FN1, PI3K/AKT signaling, promotes, trastuzumab, resistance, gastric, cancer, WTAP

The blood–brain barrier is not a simple wall but a dynamic interface built from specialized endothelial cells, pericytes, astrocyte endfeet, and a dense basement membrane. Together these components tightly regulate which molecules and cells can enter the brain, maintaining the precise ionic and metabolic environment that neurons require. In Alzheimer’s disease, imaging and post-mortem studies have repeatedly shown that this barrier becomes leaky decades before overt dementia, allowing blood-borne proteins, fibrin, thrombin, and immune cells to infiltrate brain tissue. This vascular leakage is thought to amplify neuroinflammation, impair amyloid clearance, and accelerate neuronal injury. Yet the molecular switches that flip the barrier from protective to permissive in Alzheimer’s have remained poorly defined, particularly with respect to how genetic risk translates into physical barrier breakdown.

The new work focuses on apolipoprotein E, or APOE, a lipid-transport protein produced abundantly in the brain by astrocytes and microglia. The ε4 variant of APOE is carried by roughly one in four people and multiplies Alzheimer’s risk several-fold compared with the common ε3 variant. Carriers of ε4 show earlier and more pronounced blood–brain barrier leakage, pericyte loss, and cerebral amyloid angiopathy, but the intermediate steps connecting APOE4 expression to vascular failure have been elusive. Bhattarai, Yilmaz and their colleagues reasoned that APOE4 might reprogram astrocytes, the star-shaped glial cells that normally cradle blood vessels and help maintain barrier integrity, into a state that actively undermines the very interface they are supposed to support.

Using a combination of human brain tissue analysis, Alzheimer’s disease mouse models carrying humanized APOE variants, and single-cell molecular profiling, the team discovered that astrocytes in APOE4-bearing brains dramatically upregulate the production of fibronectin, encoded by the FN1 gene. Fibronectin is an extracellular matrix glycoprotein that is normally present at very low levels in the adult brain’s vascular basement membrane. In developing tissue and in peripheral wounds, fibronectin provides a scaffold for repair, but its accumulation in the mature brain vasculature appears to be anything but helpful. The researchers found that fibronectin deposits accumulate around brain capillaries and arterioles in Alzheimer’s disease, and that this accumulation is markedly greater in individuals and animals carrying the ε4 allele.

The mechanistic story that emerges from the study is one of a vicious cycle. Amyloid-beta peptides, which accumulate in Alzheimer’s disease and deposit in cerebral blood vessels as cerebral amyloid angiopathy, stimulate astrocytes to secrete fibronectin, and APOE4 amplifies this response. The excess fibronectin then remodels the vascular basement membrane, disrupting the molecular interactions that keep endothelial tight junctions sealed and pericytes anchored to their vessels. The result is a barrier that becomes progressively more permeable, allowing plasma proteins to leak into the brain parenchyma. Some of these leaked proteins, including fibrinogen, are themselves pro-inflammatory and can further activate astrocytes and microglia, perpetuating the cycle of vascular damage and neuroinflammation that characterizes the Alzheimer’s brain.

Crucially, the researchers did not stop at correlation. In experimental models, reducing fibronectin production or interfering with its deposition produced striking protective effects. Animals with diminished fibronectin signaling maintained better barrier integrity despite the presence of APOE4 and amyloid pathology, showing less vascular leakage, reduced inflammatory activation, and improved structural preservation of the neurovascular unit. These findings position FN1 not merely as a biomarker of vascular damage but as an active, druggable participant in the disease process. The authors highlight FN1 as a potential therapeutic target, a designation that carries real weight because fibronectin biology is already well understood pharmacologically, with existing tools and compounds capable of modulating fibronectin assembly and its interactions with integrin receptors.

The implications for Alzheimer’s drug development are significant. Most therapeutic efforts to date have targeted amyloid-beta and tau, the canonical protein pathologies of the disease, with recent anti-amyloid antibodies demonstrating the ability to slow cognitive decline, albeit modestly. Vascular-targeted approaches have attracted growing interest precisely because blood–brain barrier breakdown appears so early in the disease course and correlates strongly with cognitive impairment independent of plaque burden. If fibronectin sits at the junction of genetic risk, amyloid pathology, and vascular failure, then therapies aimed at curbing fibronectin deposition could protect the barrier in ε4 carriers, a population that represents a large fraction of Alzheimer’s patients and that responds differently to some existing treatments.

The study also reframes the role of astrocytes in neurodegeneration. Long viewed primarily as support cells, astrocytes are increasingly recognized as active regulators of brain health whose dysfunction can drive disease. The finding that APOE4 pushes astrocytes toward a fibronectin-secreting, matrix-remodeling state adds to a growing body of evidence that reactive astrocyte phenotypes are not uniform and that specific astrocyte outputs, in this case a single extracellular matrix protein, can have outsized consequences for the entire neurovascular unit. It also helps explain a long-standing clinical observation: ε4 carriers tend to show more hemorrhagic and vascular contributions to their dementia, and therapies that address only amyloid may leave this vascular component untreated.

As with any study, important questions remain. The precise molecular pathway by which APOE4 sensitizes astrocytes to amyloid-driven fibronectin expression will need to be mapped in detail, and the safety of chronically inhibiting a protein that also participates in normal tissue repair must be carefully evaluated. Translating findings from mouse models and human tissue into a therapy that can be tested in patients will take years. Nevertheless, the identification of astrocyte-derived fibronectin as a mediator of APOE4-driven blood–brain barrier dysfunction provides the field with a concrete, mechanistically grounded target that connects the strongest genetic risk factor for Alzheimer’s disease to one of its earliest and most consequential pathological events. For the millions of people carrying the ε4 allele, that connection may prove to be one of the most important discoveries in the vascular dimension of Alzheimer’s research.

Subject of Research: Astrocyte-derived fibronectin mediates APOE4-driven blood–brain barrier dysfunction in Alzheimer's disease

Article Title: Fibronectin mediates APOE4-driven blood–brain barrier dysfunction in Alzheimer’s disease

Article References: Bhattarai, P., Yilmaz, E., Cakir, E. Ö., Tayran, H., Haq, I., Murphy, D., Keller, J. N., Le Grand, Q., Eschbach, J. O., Celikkaya, H., Cosacak, M. I., Yüceer Korkmaz, H., Lee, A. J., Haage, V., Ma, Y., Wang, X., Nelson, N., Lin, W., Zhang, Y., … Kizil, C. (2026). Fibronectin mediates APOE4-driven blood–brain barrier dysfunction in Alzheimer’s disease. Nature Aging, 6(9), 1901-1927. https://doi.org/10.1038/s43587-026-01204-0

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01204-0

Keywords: Alzheimer's disease, APOE4, blood–brain barrier, fibronectin, astrocytes, FN1, amyloid-beta, cerebral amyloid angiopathy, neurovascular unit, Nature Aging, therapeutic target, neuroinflammation